Neuronetics, Inc. (STIM)
NASDAQHealth CareMedical - DevicesSnapshot 2026-11-05
$2.43-10.33%
Close 2026-11-05 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-11-05
QuarterlyIQ Insights · STIM
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -72.0% |
| Our one-year growth estimate | diamond |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-11-05.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| 9.3% |
Growth built into the price is above our model estimate.
The price assumes 81.3 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-11-05 · Compared with 42 industry peers · Company calendar date is not available
STIM — credit agreement
Dated 2026-11-04
Regulation FD Disclosure. On November 4, 2026, the Company released a presentation (the “Presentation”) that it may present to certain investors. A copy of the Presentation is attached hereto as Exhibit 99.2. The information contained in Exhibit 99.2 is incorporated herein by reference. The information in this report furnished pursuant to Item 7.01, including Exhibit 99.2, shall not be deemed “filed” for the purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities o…
Why it matters: First-half revenue was $76.0 million. The $160 million to $164 million full-year target needs a strong second half.
Supportive ifOn November 4, Q3 revenue is at least $40 million and full-year revenue guidance stays at $160 million or more.
Worry ifQ3 revenue is below $40 million or full-year revenue guidance falls below $160 million.
Why it matters: Gross margin rose to 51.1% in Q2, above the full-year range. Holding near 50% would support the margin gains.
Supportive ifQ3 gross margin is at least 48%, and full-year guidance stays at 48% to 50% or higher.
Worry ifQ3 gross margin falls below 48% or management cuts the full-year margin range below 48%.
Why it matters: NeuroStar revenue fell 2.7% in Q2, even as Greenbrook revenue grew. A return to system growth would show wider sales progress.
Supportive ifQ3 NeuroStar system revenue rises from a year ago. System shipments top the 34 reported in Q1.
Worry ifQ3 NeuroStar system revenue falls year over year or shipments do not exceed 34.
Why it matters: The company reported $25 million in total cash at June 30. Its full-year cash-use range is still negative $10.5 million to negative $14.5 million.
Worry ifThe next report shows full-year cash use within or below the guided range of $10.5 million to $14.5 million.
Less concerning ifThe company raises its full-year cash-use range above $14.5 million or reports cash use above that amount.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$313 on $10,000 · ±3.1% | How much price usually moves either way. |
| Bad day | $1,053 loss on $10,000 · 10.5% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $5,693 loss on $10,000 · 56.9% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.